The Latest Breaking News from Regeneron Pharmaceuticals Inc

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Aug 3, 2022

Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis

Intellia Therapeutics Inc (NASDAQ:NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced additional interim data from the Phase 1 study of NTLA-2001, in vivo genome editing candidate for transthyretin (ATTR) amyloidosis.  Intellia had said that at the highest dose level (1.0mg/kg), six patients had shown a 93% mean reduction in the toxic protein. In the new data,…

Benzinga · Jun 24, 2022

5 Large-Cap Stocks to Buy Amid the Nasdaq’s Bear Market

The stock market indices are regaining their lost ground, somewhat. However, the tech-heavy Nasdaq Composite remains in a bear market. Hence, we think the large-cap stocks of Comcast (CMCSA), Regeneron (REGN), Microsoft (MSFT), PepsiCo (PEP), and Sanofi (SNY) might be solid bets amid the market correction. Read on.

StockNews.com · May 26, 2022

Checkmate Pharma Shares Skyrocket Over 300% On Regeneron $250M Acquisition Deal

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will acquire Checkmate Pharmaceuticals Inc (NASDAQ:CMPI) for $10.50 per share, equivalent to a total equity value of approximately $250 million. Checkmate is a clinical-stage biopharmaceutical company focused on proprietary technology to harness the immune system's power to combat cancer. The offer price represents a whopping premium of over 300% on…

Benzinga · Apr 19, 2022

Why Checkmate Pharmaceuticals Shares Are Skyrocketing

Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) shares are trading higher by 328.40% to $10.41 during Tuesday's pre-market session after Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a deal to acquire the comp

Benzinga · Apr 19, 2022

FDA Extends Review Period For Regeneron's COVID-19 Antibody Therapy

The FDA has extended its review of Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) marketing application of REGEN-COV (casirivimab and imdevimab) for non-hospitalized COVID-19 patients and as prophylaxis in certain individuals.  The extension is due to ongoing discussions with the FDA on pre-exposure prophylactic use. Regeneron has submitted additional data from its completed prophylaxis trial that the…

Benzinga · Apr 14, 2022

Michael Grimm Purchases $5.66 Million Worth Of Energy Transfer & Other Notable Insider Buys

Natural gas prices were range bound for the better part of the last decade, oscillating between $2 and $4 per million British thermal units (MMBtu) with the occasional spike outside that tight range.

Benzinga · Apr 11, 2022

How Is The Market Feeling About Regeneron Pharmaceuticals Inc?

Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) short percent of float has risen 4.85% since its last report. The company recently reported that it has 2.24 million shares sold short, which is 2.16% of all regular shares that are available for trading.

Benzinga · Apr 7, 2022

Regeneron Builds On Retinal Disease Expertise Via Gene Therapy Pact With ViGeneron

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) beefed up its gene therapy capabilities after signing a new deal with the German biotech ViGeneron. The companies did not specify their target but noted it would be some inherited retinal disease. It's an area where Regeneron has much expertise.  One of its best-selling products, Eylea, is approved to treat…

Benzinga · Apr 6, 2022

BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC

BioNTech SE (NASDAQ:BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to its FixVac candidate BNT116 combined with Libtayo (cemiplimab) in advanced non-small-cell lung cancer (NSCLC).  Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate the combination in different patient populations with advanced NSCLC and share…

Benzinga · Mar 8, 2022